Kenya study tests simpler HIV drug switch for seniors

NCT ID NCT06444620

Ongoing Disease control Sponsor: University of Nairobi Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether older adults (60+) living with HIV in Kenya can safely switch from their current three-drug pill to a simpler two-drug pill called DTG/3TC. About 240 participants who are already stable on treatment will be followed for 96 weeks. The main goal is to see if the new pill keeps the virus under control just as well.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: DTG/3TC (dolutegravir and lamivudine combination pill)
What this could lead to: If successful, this could show that switching to a simpler two-drug pill is a safe and effective option for older adults living with HIV.
What could go wrong: This is a single-arm, open-label study with no comparison group, so results may be less reliable. It only includes people already stable on another treatment, so findings may not apply to everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV-1-INFECTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

HIV infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIV-1-INFECTION

Contacts and locations

Locations

Jaramogi Oginga Odinga Teaching and Referral Hospital

Kisumu, Kenya
Kenyatta National Hospital

Nairobi, Kenya

More trials for these conditions

Other studies related to the condition(s) this trial covers.